NATPHARMA

Reinforcement of research potential for the realisation of a complete drug development scheme from natural compounds

 Partecipanti

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The aim of NatPharma is the growth and the strengthening of the RTD potential of NeaNat, a multidisciplinary research group based in Campania, one of the EU’s convergence regions. NeaNat brings together the experience and the skills of two groups with a proven expertise in the fields of isolation and identification of natural compounds (NeaMARINE) and of computer aided drug design (NeaCADD). Both groups work in the same department (Dipartimento di Chimica delle Sostanze Naturali, University of Naples 'Federico II'). The aim of NatPharma is to improve the effective capacities and research potential of NeaNat, granting the group the capacities for the successful realisation of a complete drug development scheme from natural sources to optimized drugs, including the identification, the clarification of the mechanism of action, the optimization and the biotechnological production of bioactive compounds from marine sources. Albeit our worldwide scientific excellence in the fields of research we are involved, we need new expertise in the fields of: i) biotechnology for the identification of genes involved in the biosynthesis of bioactive compounds and ii) quantum-mechanical calculations (ab-initio methods) for the investigation of the interactions occurring between organic molecules (drug candidates) and biological targets containing metals. NatPharma will address these aims by means of i) two-way secondment of staff researchers, ii) recruitment of expert researchers, iii) participation at workshops and courses, iv) organization of seminars. These actions will be integrated by the upgrading of the research equipment. Moreover, the twinning with other EU-based institutes, and the promotional activities planned will also foster a better integration of NeaNat at the European level, and will therefore foster the participation of our group in European excellence networks.'

Introduzione (Teaser)

Drug development from natural products is gaining ground in pharmaceutical industries and requires investigation of the interactions between drug candidates and biological targets containing metals. To support related research in Italy, the EU funded an upgrade of the equipment and human infrastructure of the NeaNAT group at the University of Naples.

Descrizione progetto (Article)

The drug design process has been greatly facilitated and improved by computational methods integrating quantum mechanical simulations. This is particularly applicable in calculating the interaction of enzymes involved in metallo-mediated reactions.

Based at the Dipartimento di Chimica delle Sostanze Naturali, University of Naples 'Federico II', the NeaNAT group has been actively involved in the isolation and identification of natural products of marine origin. Their recent work has expanded to include the study of biological and pharmacological activity of the isolated compounds and of their biosynthesis.

As a result, the ability to study the biogenetic pathway of a natural product is essential to keep NeaNAT in an outstanding position in its field. To achieve this, the EU-funded 'Reinforcement of research potential for the realisation of a complete drug development scheme from natural compounds' (NATPHARMA) project aimed to reinforce the research facilities and the human potential of the NeaNAT group, and improve its connections with other research institutions.

The NATPHARMA initiative contributed to this through the purchase of an Orbitrap high-resolution mass spectrometer that would significantly increase the analytical capacities of the NeaNAT group. In addition, the group acquired powerful hardware in the form of a high-performance computer (HPC) system, as well as software computational infrastructure to support the computational analysis of their data.

Additionally, researchers were recruited with expertise in biosynthetic genes and in quantum-mechanical calculations for interactions of drug candidates. This greatly increased the research potential and improved the networking expansion of the NeaNAT group with visits from leading researchers across Europe.

New techniques were acquired, such as the Terminal Restriction Fragment Length Polymorphism (T-RFLP) analysis, and projects were carried out. For example, novel FAAH and COX2 inhibitors as potential analgaesics were developed and analogues of the bioactive bacterial metabolite hormaomycin were identified.

To advertise its new competence to the international community and establish new connections with academia and companies, the NeaNAT group organised the international meeting 'NatPharma: Nature Aided Drug Discovery (NADD)'. The convention attracted over 140 participants from 9 European countries, and very positive feedback was received.

Collectively, the activities of the NATPHARMA project stand to not only enhance the scientific knowledge and capacity of the NeaNAT group, but also lead to the successful realisation of a complete drug development scheme from natural sources.